uPA is upregulated by high dose celecoxib in women at increased risk of developing breast cancer

BMC Cancer

Table 2 Median concentrations in NAF of uPA and PAI-1 (pg/mg), PGE₂ (ng/mL) and in plasma of celecoxib (ng/mL) based on celecoxib dose and menopausal status¹

Dose	N	Baseline	After Tx	Δ	P value	Celecoxib
200 mg bid ²
uPA
Overall	9	422.0	375.2	-19.6	0.10	346.0
Premen	2	133.6	130.1	-3.5	0.50	231.8
Postmen	7	645.1	402.4	-57.0	0.22	728.2
PAI-1
Overall	8	709.0	194.4	-26.7	0.56	288.1
Premen	2	2672	1821	-850.8	0.99	231.8
Postmen	6	709.0	194.4	-26.7	0.99	479.1
PGE ₂
Overall	9	8.71	13.34	-1.04	0.91	346.0
Premen	2	25.45	25.96	0.52	0.99	231.8
Postmen	7	8.71	9.80	-1.04	0.81	728.2
400 mg bid ²
uPA
Overall	11	372.6	321.6	22.0	0.46	184.0
Premen	5	372.6	321.6	11.0	0.99	0
Postmen	6	409.1	382.4	28.2	0.31	1141.8
PAI-1
Overall	5	2401	827.8	0	0.62	156.8
Premen	1	281.6	344.7	63.1	-	0
Postmen	4	2416	1437	-801.7	0.50	789.9
PGE ₂
Overall	11	12.32	13.45	-1.77	0.96	184.2
Premen	5	12.32	51.24	21.95	0.31	0
Postmen	6	14.79	13.22	-6.41	0.16	1141.8

1: N: sample size; NAF: nipple aspirate fluid. NS: not significant. Units reflect pg uPA or PAI-1/mg total protein. Δ reflects the median of the change measured in each subject (after treatment value – before treatment value) due to treatment. Celecoxib level is from plasma collected after treatment.
2: Not all NAF samples were sufficient to analyze all proteins; bid: twice daily; premen: premenopausal; postmen: postmenopausal

ISSN: 1471-2407